type 2 diabetes mellitus
Conditions
Interventions
sodium-dependent glucose co-transporter 2 inhibitors(SGLT2 inhibitors)
insulin or its analogues and oral hypoglycemic agents
Sponsors
Wakayama medical university, the first department of medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)patients with type 2 diabetes mellitus 2)ability to provide written informed consent for this study 3)inpatients 4)HbA1c>=7.0% 3)patients without change of treatment for the past 28 days
Exclusion criteria
Exclusion criteria: 1)Body Mass Index <22 2)an excessive alcohol drunker 3)patients who were added same drugs during the course of the trial 4)patients with severe ketosis, diabetic coma or precoma 5)patients with hepatic dysfunction(child-pugh B or worse) or severe renal dysfunction(eGFR<50) 6)patients with severe infection, perioperative period or severe injury 7)patients with allergy for SGLT2 inhibitors 8)patients with a history of gastrointestinal tract surgery 9)pregnant women or women that may have become pregnant 10)patients determined to be inappropriate by physician
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| changes in glycated albumin,glucagon, leptin, growth hormone, insulin-like growth factor-1, antidiuretic hormone, LDL-cholesterol, HDL-cholesterol,C-peptide immunoreactivity, sodium, body composition, body weight, blood pressure, frequency scale for symptoms of gastroesophageal reflux disease and visual analogue sacle for appetite before and after 2-week administration of SGLT2 inhibitors | — |
Primary
| Measure | Time frame |
|---|---|
| changes in plasma ghrelin level before and after 2-week administration of SGLT2 inhibitors | — |
Countries
Japan
Contacts
Public ContactTakayuki Ota
Wakayama medical university The first department of medicine
Outcome results
None listed